Dyne Therapeutics (NASDAQ:DYN) Given Buy Rating at HC Wainwright

Dyne Therapeutics (NASDAQ:DYN - Get Free Report)'s stock had its "buy" rating reaffirmed by HC Wainwright in a report released on Wednesday,Benzinga reports. They currently have a $55.00 target price on the stock. HC Wainwright's target price suggests a potential upside of 61.15% from the company's current price.

A number of other equities analysts also recently weighed in on DYN. Oppenheimer reissued an "outperform" rating and set a $55.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Guggenheim boosted their price objective on Dyne Therapeutics from $45.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, August 15th. StockNews.com lowered Dyne Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, September 16th. Stifel Nicolaus lifted their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a "buy" rating in a report on Friday, August 16th. Finally, Piper Sandler restated an "overweight" rating and set a $53.00 price target on shares of Dyne Therapeutics in a report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $51.40.

Dyne Therapeutics Stock Up 16.4 %

Shares of NASDAQ DYN traded up $4.80 during trading on Wednesday, reaching $34.13. The company had a trading volume of 2,218,238 shares, compared to its average volume of 1,495,518. The stock has a market cap of $3.43 billion, a P/E ratio of -9.59 and a beta of 1.10. The company's fifty day moving average price is $32.63 and its 200-day moving average price is $35.12. Dyne Therapeutics has a 12 month low of $9.26 and a 12 month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, equities analysts predict that Dyne Therapeutics will post -2.99 earnings per share for the current year.

Insider Buying and Selling at Dyne Therapeutics

In related news, Director Dirk Kersten sold 79,411 shares of the company's stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $36.45, for a total value of $2,894,530.95. Following the sale, the director now owns 234,127 shares in the company, valued at $8,533,929.15. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Dirk Kersten sold 79,411 shares of the company's stock in a transaction on Friday, September 20th. The stock was sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the completion of the sale, the director now owns 234,127 shares in the company, valued at approximately $8,533,929.15. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Richard William Scalzo sold 1,390 shares of the firm's stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $48,024.50. Following the transaction, the senior vice president now owns 98,568 shares in the company, valued at approximately $3,405,524.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 158,975 shares of company stock worth $5,693,789. 20.77% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP bought a new position in Dyne Therapeutics in the 3rd quarter valued at $34,000. Advantage Alpha Capital Partners LP bought a new position in Dyne Therapeutics during the third quarter valued at about $386,000. FMR LLC grew its position in Dyne Therapeutics by 69.7% during the third quarter. FMR LLC now owns 9,026,697 shares of the company's stock valued at $324,239,000 after buying an additional 3,707,734 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in Dyne Therapeutics during the third quarter worth about $430,000. Finally, Charles Schwab Investment Management Inc. raised its position in Dyne Therapeutics by 7.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 648,652 shares of the company's stock worth $23,300,000 after acquiring an additional 47,590 shares during the period. 96.68% of the stock is owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.